Novavax (NASDAQ:NVAX) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Novavax (NASDAQ:NVAX) from a sell rating to a hold rating in a report released on Thursday morning, ValuEngine reports.

Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Novavax from a hold rating to a buy rating and set a $8.00 target price for the company in a research note on Thursday, May 16th. Cantor Fitzgerald reiterated a hold rating on shares of Novavax in a research note on Thursday, May 9th. Chardan Capital reiterated a neutral rating and issued a $7.00 target price on shares of Novavax in a research note on Friday, May 10th. Oppenheimer raised their target price on shares of Novavax from $1.25 to $25.00 in a research note on Monday, May 13th. Finally, HC Wainwright reiterated a positive rating and issued a $12.00 target price (up from $10.00) on shares of Novavax in a research note on Monday, July 1st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $40.20.

NASDAQ:NVAX traded up $0.39 during mid-day trading on Thursday, hitting $4.73. The stock had a trading volume of 9,869 shares, compared to its average volume of 498,546. Novavax has a twelve month low of $4.07 and a twelve month high of $51.60. The firm has a market cap of $99.75 million, a PE ratio of -0.44 and a beta of 2.22. The stock has a 50 day simple moving average of $4.99.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.40) by $0.20. The firm had revenue of $3.98 million during the quarter, compared to analyst estimates of $4.80 million. During the same quarter last year, the business posted ($2.80) earnings per share. Analysts forecast that Novavax will post -5.77 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in NVAX. DAVENPORT & Co LLC increased its holdings in Novavax by 400.0% during the 1st quarter. DAVENPORT & Co LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 40,000 shares during the period. Wedbush Securities Inc. increased its holdings in Novavax by 102.1% during the 1st quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 27,500 shares during the period. Oppenheimer & Co. Inc. bought a new stake in Novavax during the 1st quarter worth approximately $40,000. BNP Paribas Arbitrage SA increased its holdings in Novavax by 7,685.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 79,331 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 78,312 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Novavax by 32.0% in the 4th quarter. Amalgamated Bank now owns 54,361 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 13,171 shares during the last quarter.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Featured Article: What is Cost of Capital?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.